Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial-Reference-Cited by-同舟云学术

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Published:2021-08 Issue:8 Volume:6 Page:649-658
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Vogel Arndt,Qin Shukui,Kudo Masatoshi,Su Yun,Hudgens Stacie,Yamashita Tatsuya,Yoon Jung-Hwan,Fartoux Laetitia,Simon Krzysztof,López Carlos,Sung Max,Mody Kalgi,Ohtsuka Tatsuroh,Tamai Toshiyuki,Bennett Lee,Meier Genevieve,Breder Valery

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference22 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;Ferlay;Int J Cancer,2019

2. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice;Singal;Clin Gastroenterol Hepatol,2015

3. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial;Kudo;Lancet,2018

4. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

5. Hepatocellular carcinoma: a review;Balogh;J Hepatocell Carcinoma,2016

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in Hydrogel-Based Therapies for Ovarian Cancer: A Review;Cell Biochemistry and Biophysics;2024-08-27

2. Phase I–IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies;International Journal of Molecular Sciences;2024-08-27

3. Effects of three flavonoids on the metabolism of lenvatinib;Frontiers in Pharmacology;2024-08-20

4. Small-molecule-based targeted therapy in liver cancer;Molecular Therapy;2024-08

5. Efficacy and safety of HAIC combined with tyrosine kinase inhibitors versus HAIC monotherapy for advanced hepatocellular carcinoma: a multicenter propensity score matching analysis;Frontiers in Pharmacology;2024-07-31